Inovio's PDUFA Loom: A Race to Launch with a Differentiated Profile

Inovio is one step closer to bringing INO-3107 to RRP patients, but cash runway and competitive pressure keep the risk high.

INO · Earnings Call · 2026-08-12

Final Stretch of FDA Review

Inovio’s stock has been a two-decade casualty, down ~98% from its 2020 peak, but the last 90 days show a +11.3% bounce as the company approaches a binary catalyst: an October 30 PDUFA for INO-3107, its lead candidate for recurrent respiratory papillomatosis (RRP). On the Q2 call, management reiterated that the FDA review is in its final innings. “We are on track for the October 30 target PDUFA date” — Jacqueline E. Shea, President and Chief Executive Officer · 2026-08-12 and confirmed that the agency has completed its late-cycle review and all prelicensure inspections. The tone was confident, even as the agency remains circumspect on the accelerated-approval eligibility. “We continue to believe we have provided a strong rationale for eligibility under the accelerated approval program” — Michael Sumner, Chief Medical Officer · 2026-08-12. The core of Inovio’s differentiation is the absence of the minimal residual disease surgeries that PAPZIMEOS requires. This is a recurring theme, but the company now frames it as the central competitive wedge:

INO-3.11 thousand treats RRP without requiring additional scoping and surgeries during the dosing window. In the dosing section of the prescribing information for PAPZIMEOS, scoping and surgeries to remove any papilloma are required prior to doses 3 and 4. In the Phase I/II trial for PAPZIMEOS, the vast majority (83%), of participants required at least 1 MRD surgery during the dosing window.
Steven Egge, Chief Commercial Officer · 2026-08-12

This message has been consistent since prior quarters, though the FDA’s informal meeting in July has now given management a clearer read. As the CMO put it, “We are now in the final stages of the regulatory review process” — Michael Sumner, Chief Medical Officer · 2026-08-12 - a step forward from May, when the agency had not yet scheduled the meeting. The company expects to start label negotiations in September and to secure 7 years of orphan drug exclusivity if approved.

Commercial Readiness and Cash Constraints

With approval looming, Inovio has accelerated launch preparations, including the selection of Syneos Health as its contract sales organization. The launch infrastructure is lean, targeting 300-400 laryngologists, but the financial runway remains thin. The company closed Q2 with $36.7M in cash, then raised $18.3M via a July public offering. “With the addition of the July public offering, we expect to extend our estimated cash runway into late first quarter 27” — Peter D. Kies, Chief Financial Officer · 2026-08-12. That assumes an operational net cash burn of $18M in Q3 and includes prelaunch inventory and marketing spend. The fundamentals confirm the tightness: the latest 10-Q (filed in May) shows a cash runway of just 1.7 quarters—a recurring chronic weakness for the company, which has never generated meaningful revenue. Management’s discipline on R&D spending is evident; R&D expense fell to $14M in Q1 2026 from $67M at its 2022 peak, and operating expenses were down 19% year-over-year in Q2. The net loss of $6M was helped by a noncash warrant gain, but the underlying burn is real. Analysts on the call pressed on future capital needs, and while the company claims to be funded “through the projected launch,” the ambiguity around confirmatory-trial costs and commercial ramp keeps the risk of dilution alive.

Platform Validation and the Path Forward

Beyond INO-3107, the quarter also delivered a partner milestone: ApolloBio’s positive Phase III for VGX-3100 in China, a validation of the DNA medicine platform. Jackie Shea highlighted this as evidence of the potential of DNA medicines to treat HPV-related diseases. Yet the company’s focus remains laser-tight on the upcoming PDUFA, with other pipeline assets (DPROT, etc.) deprioritized until funding is secured. The market is clearly pricing in binary risk. The recent 90-day chart shows a sharp 42% drawdown in May followed by a 60% rebound, reflecting hopes and fears around the FDA decision. Inovio’s historical cash burn has been a constant theme, but the company now sees a finish line. Whether the FDA deems INO-3107’s efficacy and safety sufficient for accelerated approval remains the key question. With a new standard of care potentially within reach, the next few months will be pivotal. The company’s own confidence is anchored in a clinical efficacy profile that could displace the incumbent, but investors will be watching the confirmatory trial design and the cash position closely.